Prof. Dr. rer. nat.

Hans-Ulrich Demuth

Fraunhofer Institute for Cell Therapy and Immunology (IZI) Leipzig

Focus of the Commitment in the German Ethics Council

  • Collaboration on recommendations about questions of medical ethics in society and politics
  • Connection between academic and industrial research and its promotion
  • Scientific aspects of social issues

Contact for Press Enquiries on the Following Topics

  • Type II diabetes, Alzheimer's disease
  • Science education as a basis for rational decision-making in politics
  • Questions concerning drug research and pharmaceutical research

Born in 1953

Professional Background

  • 2015-2020 Acting Director of the Bioanalytics and Bioprocesses branch (IZI-BB) at the Fraunhofer IZI in Potsdam-Golm
  • 2013-2020 Head of the Department of Drug Design and Target Validation (MWT) at the Fraunhofer IZI in Halle (Saale)
  • 2006 Professor for Pharmabiotechnology at the Anhalt University of Applied Sciences
  • 2003 Lectureship in Protein Biotechnology at the Anhalt University of Applied Sciences
  • 2001-2013 Founder and Scientific Director of Probiodrug AG in Halle (Saale)
  • 1996-2002 Lectureship for Enzymology at the Friedrich Schiller University Jena
  • 1994-2000 Head of the Department of Drug Biochemistry at the Hans Knöll Institute (HKI) in Jena
  • 1990 Habilitation and facultas docendi for Biochemistry at the Martin Luther University Halle-Wittenberg
  • 1981-1989 Assistant and Senior Assistant at the Martin Luther University Halle-Wittenberg
  • 1973-1981 Study of Biochemistry and doctorate


  • Since April 2020 Member of the German Ethics Council
  • Member of the (German) Society for Biochemistry and Molecular Biology (GBM)
  • Member of The Protein Society (TPS)
  • Member of the International Proteolysis Society (IPS)
  • Member of the American Diabetes Association (ADA)
  • Member of the American Chemical Society (ACS)
  • Member of the European Association for the Study of Diabetes (EASD)
  • Member of the New York Academy of Sciences (NYAS)
  • Member of the Society for Neuroscience (SfN)
  • Member of the Alzheimer’s Association (ISTAART)
  • Jury member of the IQ Innovation Award of the Metropolitan Region Central Germany
  • Member of the Halle-Saalkreis Lions Club


  • 2013 Hugo Junkers Prize for Research and Innovation in Saxony-Anhalt
  • 2010 IQ Innovation Award Central Germany (overall winner)
  • 1989 Johannes Müller Prize of the Society for Experimental Medicine

Publications (Selection)

  • Grochwaska, K. et al. (2017): Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction. In: EMBO Reports, 18 (6), 962-981.
  • Nussbaum, J. M. et al. (2012): Prion-Like Behavior and Tau-dependent Cytotoxicity of β-Amyloid Oligomers Seeded by Pyroglutamylated β-Amyloid. In: Nature, 485 (7400), 651-655.
  • Cynis, H. et al. (2011): Inhibition of a glutaminyl cyclase isoenzyme mediates deactivation of CCL2: a therapeutic approach for inflammatory disorders. In: Molecular Medicine, 3 (9), 545-558.
  • Schilling, S. et al. (2008): Inhibition of glutaminyl cyclase – a novel therapeutic concept for the causative treatment of Alzheimer's disease. In: Nature Medicine, 14, 1106-1111.
  • Hoffmann, T. et al. (2001): DPPIV-inhibition as treatment of type II diabetes. In: Mitzutani, S. et al. (ed.): Cell-Surface aminopeptidases. Elsevier, 381-387.
  • Pederson, R. A. et al. (1998): Improved glucose tolerance in zucker fatty rats treated by oral administration of the dipeptidyl peptidase IV inhibitor isoleucyl thiazolidide. In: Diabetes, 47, 1253-1258.